Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

Ebola Clinical Trial

Official title:
A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M™ Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age

Status Completed

Clinical Trial Summary

This is a randomized, observer-blind, placebo-controlled trial in male and female subjects ≥18 to <50 years of age. Subjects will be healthy adults based on history, physical examination, and baseline clinical laboratory testing. Approximately 230 eligible subjects will be enrolled into 1 of 13 treatment groups. Treatments will comprise two IM doses at a 21-day interval (Day 0 and Day 21), in alternate deltoids with the test article assigned (i.e., saline placebo, dose of EBOV GP vaccine with or without Matrix-M adjuvant), in a 0.5mL injection volume.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02370589
Study type	Interventional
Source	Novavax
Contact
Status	Completed
Phase	Phase 1
Start date	February 2015
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05284097` - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study	Phase 2
Completed	`NCT02240875` - A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo	Phase 1
Completed	`NCT05064956` - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)	Phase 2
Completed	`NCT05079750` - A Study of a New Vaccine Against Two Types of Ebola	Phase 1
Completed	`NCT04385719` - Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy	Phase 2
Active, not recruiting	`NCT05301504` - A Study in Tanzania of a New Vaccine Against Two Types of Ebola	Phase 1
Completed	`NCT00646152` - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study	Phase 1
Completed	`NCT02818582` - GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen	Phase 2
Completed	`NCT04228783` - A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants	Phase 3
Active, not recruiting	`NCT03031912` - African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola	Phase 2